BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment In Vivo BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days’ oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: DBA/1J mice injected with collagen as a CIA model Dosage: 30 mg/kg Administration: oral gavage; 21 days; once daily Result: Decreased arthritis scores significantly when it compares to control group. Form:Solid IC50& Target:IC50: Bruton kinase (BTK)